Targeting EGFR in esophagogastric cancer Review
| Authors: | Maron, S. B.; Xu, J.; Janjigian, Y. Y. |
| Review Title: | Targeting EGFR in esophagogastric cancer |
| Abstract: | Esophagogastric cancer (EGC) remains a major cause of cancer-related mortality. Overall survival in the metastatic setting remains poor, with few molecular targeted approaches having been successfully incorporated into routine care to-date: only first line anti-HER2 therapy in ERBB2-expressing tumors, second line anti-VEGFR2 therapy with ramucirumab in unselected patients, and pembrolizumab in PD-L1 expressing or MSI-H patients. EGFR inhibitors were extensively studied in EGC, including phase III trials with cetuximab (EXPAND), panitumumab (REAL3), and gefitinib (COG). All three trials were conducted in unselected populations, and therefore, failed to demonstrate clinical benefit. Here, we review previous attempts at targeting EGFR in EGC and potential future biomarkers for targeting this pathway in patients with EGFR-amplified tumors. © Copyright © 2020 Maron, Xu and Janjigian. |
| Keywords: | epidermal growth factor receptor; cetuximab; panitumumab; targeted therapy; esophageal cancer; gastric cancer; gastroesophageal cancer; ctdna |
| Journal Title: | Frontiers in Oncology |
| Volume: | 10 |
| ISSN: | 2234-943X |
| Publisher: | Frontiers Media S.A. |
| Date Published: | 2020-12-08 |
| Start Page: | 553876 |
| Language: | English |
| DOI: | 10.3389/fonc.2020.553876 |
| PROVIDER: | scopus |
| PMCID: | PMC7753114 |
| PUBMED: | 33364187 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 4 January 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work